COMMUNIQUÉS West-GlobeNewswire

National Patient Survey Highlights Healthcare Challenges for the 1 in 4 Americans Living with Rheumatic Disease
13/09/2019
- 60% of respondents reported difficulty affording treatment -- Nearly half of respondents reported undergoing step therapy -- Two-thirds of respondents reported activity and lifestyle limitations due to their disease [...]
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
13/09/2019
Tonya Winders, CEO, Allergy & Asthma Network Joins Intrommune Therapeutics Advisory Board New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , a New York-based biotechnology company developing the [...]
Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS
13/09/2019
Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) versus teriflunomide in patients with relapsing multiple sclerosis (RMS) were presented at the 35th Congress of the [...]
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
13/09/2019
Hamilton, Bermuda, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology [...]
NimbleRx Officially Introduces Itself as First Delivery Service Designed for Independent and Local Pharmacies
13/09/2019
Nimble has already partnered with 600 pharmacies in the US and reached $150 million in annual GMV REDWOOD CITY, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- NimbleRx today formally unveiled itself as the first service [...]
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
13/09/2019
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS)[1]; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 positive B-cells, [...]
Weight Watchers International, Inc. to Change its Legal Name to WW International, Inc. Following Rebranding Last Year
13/09/2019
NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- WW (NASDAQ: WW), a global wellness company and the world’s leading commercial weight management program, today announced that it will be changing its legal name from Weight [...]
Philips Global Beauty Index reveals that women want personalized beauty solutions to meet their unique needs
13/09/2019
September 13, 2019 Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), today released the findings of its fifth annual Philips Global Beauty Index, surveying over 12,000 women from 12 different countries [...]
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
13/09/2019
NEW YORK and LONDON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where [...]
Salarius Pharmaceuticals Announces Senior Leadership Changes
13/09/2019
Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer HOUSTON, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage [...]
Akesis Galaxy™ SRS System Receives 510(k) Clearance
13/09/2019
CONCORD, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- The Akesis Galaxy™, a gamma stereotactic radiosurgery system (SRS) with continuous 360 o rotational technology, has received 510(k) clearance from the U.S. Food and [...]
Nexstim Plc Agrees on a New Loan Repayment Schedule with Kreos
13/09/2019
Company announcement, Helsinki, 13 September 2019 at 3.00 pm (EEST) Nexstim Plc Agrees on a New Loan Repayment Schedule with Kreos Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and [...]
VitalHub Announces Commencement of Second Phase of Licensing Agreement with The Salvation Army Toronto Grace Health Centre
13/09/2019
TORONTO, Sept. 13, 2019 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company”) (TSXV: VHI) is pleased to announce that upon successful completion of the first phase of the project, it has entered phase two of the B Care EHR [...]
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
13/09/2019
REHOVOT, Israel and SINGAPORE, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF) , a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of [...]
Microbot Medical Announces Outcome of Annual Meeting of Shareholders
13/09/2019
Maintains Regulatory Pre-Submission Timeline of the Self-Cleaning Shunt (SCS TM ) HINGHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Having successfully executed a number of significant milestones over the past twelve [...]
Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer
13/09/2019
- Gregory Went, Ph.D., Founder, transitions to a strategic advisory role - David Mahoney, lead independent director, appointed to Chairman of the Board EMERYVILLE, Calif., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Adamas [...]
Helius Medical Technologies, Inc. Announces Addition of a New PoNS™ Clinic in Quebec City, Canada
13/09/2019
NEWTOWN, Pa., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that Clinique [...]
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
13/09/2019
NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in [...]
Vectura provides update on GSK Litigation
13/09/2019
Vectura provides update on GSK Litigation Chippenham, UK – 13 September 2019 : Vectura Group plc (LSE: VEC) ("Vectura" or "the Group") announces that following the award of US$89.7m in damages to Vectura by a jury in [...]

Pages